News on Mesothelioma | Surviving Mesothelioma

10-Year Study Confirms Longer Mesothelioma Survival with Trimodal Therapy

Surgery for Peritoneal Mesothelioma

Trimodality therapy including surgery, chemotherapy, and radiation appears to give carefully-selected patients the best odds of surviving mesothelioma. In a new article in the Journal of Clinical Oncology, researchers from MD Anderson Cancer Center detail the results of their analysis of mesothelioma survival using the National Cancer Database. Long-Term Mesothelioma Research The research team started with a pool of 20,561 pleural mesothelioma cases diagnosed between … Continue reading 10-Year Study Confirms Longer Mesothelioma Survival with Trimodal Therapy »

These Proteins Appear to Shorten Mesothelioma Survival

New evidence suggests that mesothelioma patients whose tumors express two particular proteins do not live as long as other mesothelioma patients. An international team of scientists including mesothelioma researchers at the National Cancer Institute say ALCAM (also called CD166) and PD-L1 (CD274) are both associated with “significantly decreased” survival in pleural mesothelioma. Understanding ALCAM and PD-L1 ALCAM is a type I transmembrane protein that regulates … Continue reading These Proteins Appear to Shorten Mesothelioma Survival »

Thoracoscopy Deemed “Valuable and Safe” for Mesothelioma Patients

Pleural mesothelioma patients who are recommended for medical thoracoscopy can rest assured that the procedure is “a valuable and safe” diagnostic tool. That is the message from Chinese researchers after an analysis of nine years of medical thoracoscopies on more than 800 patients with malignant mesothelioma and other pleural cancers at a Beijing hospital. What is Medical Thoracoscopy? Medical thoracoscopy is a minimally invasive procedure … Continue reading Thoracoscopy Deemed “Valuable and Safe” for Mesothelioma Patients »

Novel Chemotherapy Technique Appears to Boost Mesothelioma Survival

German surgeons are reporting on a potential new way to improve outcomes for people with malignant pleural mesothelioma by infusing chemotherapy drugs in an isolated area and then removing them. In an article in OncoTargets and Therapy, surgical oncologists from Burghausen, Germany say they were prompted to test the new technique after radical mesothelioma surgery “failed to translate into a definite survival advantage.” Mesothelioma Treatment Risks Although … Continue reading Novel Chemotherapy Technique Appears to Boost Mesothelioma Survival »

The Economic Burden of Malignant Mesothelioma

Patients with malignant mesothelioma and their families are not the only ones impacted by the costs associated with the asbestos-linked cancer. There is also a societal economic burden that can run into the hundreds of millions of dollars. That is the conclusion of a new report published by Canadian occupational medicine and public health experts in the journal Occupational and Environmental Medicine. A History of … Continue reading The Economic Burden of Malignant Mesothelioma »

Malignant Mesothelioma Risk May Eventually Plateau

Mesothelioma Incidence Among Shipbreakers

The risk for developing malignant pleural mesothelioma after asbestos exposure may not increase indefinitely. Researchers in Italy say the chances of contracting the lung-related type of asbestos cancer appear to top out at about 40 years. Unfortunately, the same is not true of peritoneal mesothelioma, which occurs in the abdomen. The risk also continues to increase for lung and ovarian cancer. Cancer Risk from Asbestos … Continue reading Malignant Mesothelioma Risk May Eventually Plateau »

Long-Term Peritoneal Mesothelioma Survival with Apitolisib

There is hopeful news this week about the survivability of peritoneal mesothelioma, particularly when relapses are treated with a powerful drug called apitolisib. Peritoneal mesothelioma is a less common form of the rare asbestos-related cancer, malignant mesothelioma. It starts on the membrane that surround the abdominal organs and can quickly spread throughout the abdomen. According to the National Cancer Institute, the one-year survival rates for … Continue reading Long-Term Peritoneal Mesothelioma Survival with Apitolisib »

Radiotherapy for Lymphoma as a Risk Factor for Malignant Mesothelioma

People who received radiotherapy for the treatment of lymphoma have a higher chance of developing malignant mesothelioma later in life. That is the conclusion of a large, population-based study of American lymphoma patients over four decades. A Closer Look at the Data Using data from the US Surveillance, Epidemiology, and End Results (SEER) database, researchers at Stanford Cancer Center and scientific consulting firm Exponent, Inc. … Continue reading Radiotherapy for Lymphoma as a Risk Factor for Malignant Mesothelioma »

Antibody-Drug Conjugate Fails to Stop Recurrent Pleural Mesothelioma

A new drug designed to treat recurrent malignant mesothelioma while minimizing side effects has failed to meet expectations. Anetumab ravtansine, is an antibody-drug conjugate (ADC) developed with biotechnology firms ImmunoGen and MorphoSys and owned by Bayer.  It had been the focus of a Phase II clinical trial for pleural mesothelioma. The trial has now been stopped. Understanding ADCs Many of the most dangerous side effects of … Continue reading Antibody-Drug Conjugate Fails to Stop Recurrent Pleural Mesothelioma »

Second-Line Immunotherapy Treatment Fails to Improve Mesothelioma Survival

A large international clinical trial of the immunotherapy drug tremelimumab as a second- or third-line treatment option for malignant mesothelioma has produced some disappointing news. Drug maker AstraZeneca has just released an update on the ongoing DETERMINE trial which suggests that the survival rates are roughly the same for previously-treated mesothelioma patients whether they later received treatment with tremelimumab or a placebo. What is Tremelimumab? … Continue reading Second-Line Immunotherapy Treatment Fails to Improve Mesothelioma Survival »

Get your free copy of
“Surviving Mesothelioma” Today!